The left has become unhinged over the election of Donald Trump. They are going nuts trying to stop everything Trump does. They will not accept the fact that they lost the election for President and remain a minority in the House and the Senate.
Their actions are unprecedented. They are going after every Trump nomination simply because Trump made the selection. They are trying to discredit the election. They are boycotting the inauguration. They are planting false stories in the media. They are opposing everything that Trump was elected to do.
The biased ferocity of the media against Trump is unprecedented. You will find no favorable news about Trump in the so called “mainstream media”; none.
They are truly unhinged.
Trump to CNN: Retract “blatantly false story” on Tom Price
From Hot Air: JANUARY 18, 2017, BY ED MORRISSEY
Does HHS Secretary nominee Tom Price have a conflict-of-interest problem — or does CNN have a credibility problem? Two days ago, CNN’s Manu Raju reported that Price had purchased stock in a company that would benefit from legislation he had drafted just prior to introducing it to the House. That would violate House rules and create a big problem for his confirmation hearing, which starts today:
- Rep. Tom Price last year purchased shares in a medical device manufacturer days before introducing legislation that would have directly benefited the company, raising new ethics concerns for President-elect Donald Trump’s nominee for Health and Human Services secretary.
Price bought between $1,001 to $15,000 worth of shares last March in Zimmer Biomet, according to House records reviewed by CNN.
Less than a week after the transaction, the Georgia Republican congressman introduced the HIP Act, legislation that would have delayed until 2018 a Centers for Medicare and Medicaid Services (CMS) regulation that industry analysts warned would significantly hurt Zimmer Biomet financially once fully implemented.
Zimmer Biomet, one of the world’s leading manufacturers of knee and hip implants, was one of two companies that would have been hit the hardest by the new CMS regulation that directly impacts the payments for such procedures, according to press reports and congressional sources.
After Price offered his bill to provide Zimmer Biomet and other companies relief from the CMS regulation, the company’s political action committee donated to the congressman’s reelection campaign, records show.
Almost immediately, the national media picked up the story. But was it accurate? Ellen Carmichael, who worked as Price’s aide at one time, ripped CNN for “journalistic malpractice” on Twitter, and provided the missing context in Raju’s reporting:
- Ellen L. Carmichael @ellencarmichael
Good morning, all. Who’s ready to see the Price CNN story debunked from start to finish? Here we go… (1/x)
Ellen L. Carmichael @ellencarmichael
.@RepTomPrice has a Morgan Stanley brokered-directed stock portfolio. He is not personally engaged in trades made on his behalf. (2/x)
7:05 AM – 17 Jan 2017
Ellen L. Carmichael @ellencarmichael
CNN says that @RepTomPrice introduced legislation after purchasing stock. This is demonstrably false. Work on this began in 2015! (5/x)
Twitchy has the entire tweetstorm. The Daily Caller picked up on Carmichael’s testimony:
Importantly, Price played no role in the decision to purchase the stock, which was executed under a broker-directed account by Morgan Stanley, according to a knowledgeable source. The stock purchase was by his brokerage firm during a regular rebalancing of accounts.
The congressman — who for two decades was an orthopedic surgeon — also went on record opposing the CMS regulation six months before the stock selection had been made.
On Sept. 21, 2015 Price joined 60 Democrats and Republicans who questioned the Obama administration’s new, controversial Medicare reimbursement policy. In the letter, the group asked Andy Slavitt, the CMS acting administrator, to delay the regulation.
Further, Price introduced his legislation before he knew of the stock purchase. He was the chief sponsor of the HIP Act and he introduced it on March 23, 2016, according to House records. But Morgan Stanley did not inform Price of the Zimmer Biomet stock until April 14, according to House financial disclosure forms on the Georgia congressman’s transactions.
That does tend to put a hole in the conflict-of-interest story, especially the last bullet. How can there be a conflict of interest when the principal is unaware of the interest? That hasn’t kept Chuck Schumer from being … well, Chuck Schumer:
- Senate Minority Leader Chuck Schumer (D-N.Y.) on Monday night renewed his calls on the Office of Congressional Ethics to launch an investigation into potential violations of the STOCK Act by Rep. Tom Price (R-Ga.), President-elect Donald Trump’s nominee to lead the department of Health and Human Services.
“The President-elect claims he wants to drain the swamp, but Congressman Price has spent his career filling it up,” Schumer said.
Schumer, who made the comments in a statement and on Twitter, was responding to a CNN report published earlier in the day alleging that Price had purchased shares in a medical device manufacturer last March “days before introducing legislation that would have directly benefited the company.” CNN also reported that the company’s political action committee donated to the congressman’s re-election campaign after the legislation was introduced.